NO20070917L - Imidazotriaziner som protein-kinaseinhibitorer - Google Patents

Imidazotriaziner som protein-kinaseinhibitorer

Info

Publication number: NO20070917L
Authority: NO; Norway
Prior art keywords: imidazotriazines; protein kinase; kinase inhibitors; treatment; igf1r
Prior art date: 2004-07-20

Application number

NO20070917A

Other languages

English (en)

Norwegian (no)

Inventor

Andrew Philip Crew

Mark Joseph Mulvihill

Douglas Scott Werner

Original Assignee

Osi Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-20

Filing date

2007-02-16

Publication date

2007-03-19

2007-02-16 Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc

2007-03-19 Publication of NO20070917L publication Critical patent/NO20070917L/no

Links

XZLIYCQRASOFQM-UHFFFAOYSA-N 5h-imidazo[4,5-d]triazine Chemical class N1=NC=C2NC=NC2=N1 XZLIYCQRASOFQM-UHFFFAOYSA-N 0.000 title 1
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
239000003909 protein kinase inhibitor Substances 0.000 title 1
101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 abstract 1
102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 abstract 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
208000037765 diseases and disorders Diseases 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
AIDS & HIV (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)

NO20070917A 2004-07-20 2007-02-16 Imidazotriaziner som protein-kinaseinhibitorer NO20070917L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US58951404P	2004-07-20	2004-07-20
PCT/US2005/025891 WO2006012422A1 (en)	2004-07-20	2005-07-20	Imidazopyrazine as tyrosine kinase inhibitors

Publications (1)

Publication Number	Publication Date
NO20070917L true NO20070917L (no)	2007-03-19

Family

ID=35482337

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20070917A NO20070917L (no)	2004-07-20	2007-02-16	Imidazotriaziner som protein-kinaseinhibitorer

Country Status (18)

Country	Link
US (1)	US7741324B2 (pt)
EP (1)	EP1781660A1 (pt)
JP (1)	JP4918038B2 (pt)
KR (1)	KR20070035087A (pt)
CN (1)	CN101084218A (pt)
AP (1)	AP2007003924A0 (pt)
AR (1)	AR053090A1 (pt)
AU (1)	AU2005267120B2 (pt)
BR (1)	BRPI0513565A (pt)
CA (1)	CA2574594A1 (pt)
EA (1)	EA200700220A1 (pt)
IL (1)	IL180806A0 (pt)
MX (1)	MX2007000822A (pt)
MY (1)	MY139689A (pt)
NO (1)	NO20070917L (pt)
RU (1)	RU2007106068A (pt)
TW (1)	TW200613306A (pt)
WO (1)	WO2006012422A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7026500B2 (en) *	2000-08-24	2006-04-11	University Of Tennessee Research Foundation	Halogenated selective androgen receptor modulators and methods of use thereof
TWI378934B (en)	2004-04-02	2012-12-11	Osi Pharm Inc	6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
EP2385053B1 (en) *	2005-11-17	2013-10-02	OSI Pharmaceuticals, Inc.	Intermediates for the preparation of fused bicyclic mTOR inhibitors
US8575164B2 (en) *	2005-12-19	2013-11-05	OSI Pharmaceuticals, LLC	Combination cancer therapy
US7659274B2 (en) *	2006-01-25	2010-02-09	Osi Pharmaceuticals, Inc.	Unsaturated mTOR inhibitors
ME02372B (me)	2006-11-22	2016-06-20	Incyte Holdings Corp	Imidazotriazini i imidazopiramidini kao inhibitori kinaze
US20120101114A1 (en)	2007-03-28	2012-04-26	Pharmacyclics, Inc.	Inhibitors of bruton's tyrosine kinase
IL295053A (en) *	2007-03-28	2022-09-01	Pharmacyclics Llc	Broton tyrosine kinase inhibitors
CN103645459B (zh) *	2007-05-01	2016-03-30	高通股份有限公司	无线通信系统的定位
US8130700B2 (en)	2007-06-15	2012-03-06	Silver Spring Networks, Inc.	Method and system for providing network and routing protocols for utility services
JP2011510018A (ja) *	2008-01-18	2011-03-31	オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド	癌治療のためのイミダゾピラジノール誘導体
WO2009117482A1 (en) *	2008-03-19	2009-09-24	Osi Pharmaceuticals, Inc	Mtor inhibitor salt forms
EP2283020B8 (en) *	2008-05-19	2012-12-12	OSI Pharmaceuticals, LLC	Substituted imidazopyr-and imidazotri-azines
WO2009143211A2 (en)	2008-05-21	2009-11-26	Incyte Corporation	Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
EP2313102A2 (en) *	2008-07-03	2011-04-27	Biota Scientific Management	Bycyclic nucleosides and nucleotides as therapeutic agents
DE102009005193A1 (de) *	2009-01-20	2010-07-22	Merck Patent Gmbh	Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren
WO2010123792A1 (en)	2009-04-20	2010-10-28	Osi Pharmaceuticals, Inc.	Preparation of c-pyrazine-methylamines
EP2427192A1 (en) *	2009-05-07	2012-03-14	OSI Pharmaceuticals, LLC	Use of osi-906 for treating adrenocortical carcinoma
EA025304B1 (ru) *	2010-02-03	2016-12-30	Инсайт Холдингс Корпорейшн	ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
EP2544672A1 (en)	2010-03-09	2013-01-16	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
CN107898791A (zh)	2010-06-03	2018-04-13	药品循环有限责任公司	布鲁顿酪氨酸激酶(btk)抑制剂的应用
CA2825894C (en)	2011-02-02	2021-11-30	Amgen Inc.	Prognosis of cancer using a circulating biomarker
KR101548443B1 (ko)	2011-02-23	2015-08-28	화이자 인코포레이티드	신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진
US9138436B2 (en)	2011-07-13	2015-09-22	Pharmacyclics Llc	Inhibitors of Bruton's tyrosine kinase
CA2852127C (en)	2011-11-11	2020-10-27	Duke University	Combination drug therapy for the treatment of solid tumors
US8377946B1 (en)	2011-12-30	2013-02-19	Pharmacyclics, Inc.	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
BR112014018199A8 (pt)	2012-01-26	2021-03-02	H Lundbeck As	inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
CN103374001B (zh) *	2012-04-19	2015-10-28	山东轩竹医药科技有限公司	咪唑并三嗪类mTOR抑制剂
JO3754B1 (ar)	2012-06-04	2021-01-31	Pharmacyclics Llc	أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
US8980259B2 (en)	2012-07-20	2015-03-17	Novartis Ag	Combination therapy
CN104704129A (zh)	2012-07-24	2015-06-10	药品循环公司	与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
EA201590855A1 (ru)	2012-11-15	2015-11-30	Фармасайкликс, Инк.	Соединения пирролопиримидина как ингибиторы киназ
CA2925124A1 (en)	2013-09-30	2015-04-02	Pharmacyclics Llc	Inhibitors of bruton's tyrosine kinase
US20210317140A1 (en) *	2013-10-18	2021-10-14	Medivation Technologies, Inc.	Heterocyclic Compounds and Methods of Use
WO2015081783A1 (zh) *	2013-12-06	2015-06-11	江苏奥赛康药业股份有限公司	吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
WO2015143400A1 (en)	2014-03-20	2015-09-24	Pharmacyclics, Inc.	Phospholipase c gamma 2 and resistance associated mutations
AU2015296215A1 (en)	2014-08-01	2017-03-23	Pharmacyclics Llc	Inhibitors of bruton's tyrosine kinase
SG11201700849XA (en)	2014-08-07	2017-03-30	Pharmacyclics Llc	Novel formulations of a bruton's tyrosine kinase inhibitor
IL315294A (en)	2015-03-03	2024-10-01	Pharmacyclics Llc	Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
HRP20240082T1 (hr)	2015-07-07	2024-03-29	H. Lundbeck A/S	Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
US10053465B2 (en)	2015-08-26	2018-08-21	Incyte Corporation	Pyrrolopyrimidine derivatives as TAM inhibitors
WO2017129763A1 (en)	2016-01-28	2017-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
MD3436461T2 (ro)	2016-03-28	2024-05-31	Incyte Corp	Compuși pirolotriazină ca inhibitori TAM
MA46995A (fr)	2016-12-03	2019-10-09	Acerta Pharma Bv	Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
SI3687996T1 (sl)	2017-09-27	2022-04-29	Incyte Corporation	Soli pirolotriazinskih derivatov, ki so uporabne kot zaviralci TAM
FI3801526T3 (fi)	2018-05-25	2024-03-20	Cardurion Pharmaceuticals Inc	6-[(3s,4s)-4-metyyli-1-(pyrimidin-2-yylimetyyli)pyrrolidin-3-yyli]-3-tetrahydropyran-4-yyli-7h-imidatso[1,5-a]pyratsin-8-onin monohydraattimuotoja ja kiteisiä muotoja
MD3813800T2 (ro)	2018-06-29	2025-10-31	Incyte Corp	Formulări de inhibitor al AXL/MER
EP3843737A4 (en)	2018-08-31	2022-06-01	Imara Inc.	PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
EP4114401A1 (en)	2020-03-06	2023-01-11	Incyte Corporation	Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
AU2023249795A1 (en) *	2022-04-08	2024-10-17	Shy Therapeutics, Llc	Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5217999A (en)	1987-12-24	1993-06-08	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE69105495T2 (de)	1990-04-02	1995-04-06	Pfizer	Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en)	1990-04-16	1994-04-12	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5409930A (en)	1991-05-10	1995-04-25	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6645969B1 (en)	1991-05-10	2003-11-11	Aventis Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
EP0586608A1 (en)	1991-05-29	1994-03-16	Pfizer Inc.	Tricyclic polyhydroxylic tyrosine kinase inhibitors
MX9304801A (es)	1992-08-06	1997-06-28	Warner Lambert Co	2-toindoles (selenoidoles) disulfuros (seleniduros) relacinados, los cuales inhiben a las proteinas tirosina cinasas y los cuales tienen propiedades anti-tumorales.
WO1994003427A1 (en)	1992-08-06	1994-02-17	Warner-Lambert Company	2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
GB9226855D0 (en)	1992-12-23	1993-02-17	Erba Carlo Spa	Vinylene-azaindole derivatives and process for their preparation
JPH07133280A (ja)	1993-11-09	1995-05-23	Takeda Chem Ind Ltd	セフェム化合物、その製造法および抗菌組成物
US5584409A (en) *	1995-09-18	1996-12-17	Chemberlen; Christopher H.	One direction ventilation valves
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
CH690773A5 (de)	1996-02-01	2001-01-15	Novartis Ag	Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
EP0888310B1 (en)	1996-03-15	2005-09-07	AstraZeneca AB	Cinnoline derivatives and use as medicine
US6232299B1 (en)	1996-05-01	2001-05-15	Eli Lilly And Company	Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
EP0915698A4 (en)	1996-05-01	1999-08-11	Lilly Co Eli	TREATMENT PROCEDURE FOR VEGF-RELATED DISEASES
UA54427C2 (uk)	1996-05-01	2003-03-17	Елі Ліллі Енд Компані	Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
GB9707800D0 (en)	1996-05-06	1997-06-04	Zeneca Ltd	Chemical compounds
CA2344249A1 (en)	1998-09-18	2000-03-30	Basf Aktiengesellschaft	Pyrrolopyrimidines as protein kinase inhibitors
US6337338B1 (en)	1998-12-15	2002-01-08	Telik, Inc.	Heteroaryl-aryl ureas as IGF-1 receptor antagonists
US6982265B1 (en)	1999-05-21	2006-01-03	Bristol Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
DE60026297T2 (de) *	1999-05-21	2006-11-02	Bristol-Myers Squibb Co.	Pyrrolotriazin kinasehemmer
WO2001072751A1 (en) *	2000-03-29	2001-10-04	Knoll Gesellschaft Mit Beschraenkter Haftung	Pyrrolopyrimidines as tyrosine kinase inhibitors
MXPA03008560A (es)	2001-03-22	2004-06-30	Abbot Gmbh & Co Kg	Pirazolopirimidinas como agentes terapeuticos.
AR035885A1 (es)	2001-05-14	2004-07-21	Novartis Ag	Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
SE0102168D0 (sv)	2001-06-19	2001-06-19	Karolinska Innovations Ab	New use and new compounds
JP3933420B2 (ja) *	2001-07-24	2007-06-20	出光ユニテック株式会社	収納袋の排気弁
US7115617B2 (en)	2001-08-22	2006-10-03	Amgen Inc.	Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en)	2001-08-22	2005-09-06	Amgen Inc.	Substituted pyrimidinyl derivatives and methods of use
IL160915A0 (en)	2001-09-19	2004-08-31	Aventis Pharma Sa	Indolizines inhibiting kinase proteins
GB0122560D0 (en)	2001-09-19	2001-11-07	Aventis Pharma Ltd	Chemical compounds
US6827492B2 (en) *	2001-12-05	2004-12-07	Leland B. Cook	One-way concealed-valve vented storage bag
SE0104140D0 (sv)	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
US20050215564A1 (en)	2002-02-14	2005-09-29	Stiles Charles D	Methods and compositions for treating hyperproliferative conditions
ES2283744T3 (es)	2002-02-14	2007-11-01	Dana-Farber Cancer Institute, Inc.	Metodos y composiciones para el tratamiento de condiciones hiperproliferativas.
DE10230604A1 (de) *	2002-07-08	2004-01-29	Bayer Ag	Heterocyclisch substituierte Imidazotriazine
DE10230605A1 (de) *	2002-07-08	2004-01-29	Bayer Ag	Substituierte Imidazotriazine
UA80171C2 (en)	2002-12-19	2007-08-27	Pfizer Prod Inc	Pyrrolopyrimidine derivatives
JP3910627B2 (ja)	2003-03-12	2007-04-25	ファイザー・プロダクツ・インク	ピリジルオキシメチルおよびベンゾイソオキサゾールのアザビシクロ環の誘導体
TWI378934B (en) *	2004-04-02	2012-12-11	Osi Pharm Inc	6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors

2005
- 2005-07-19 TW TW094124340A patent/TW200613306A/zh unknown
- 2005-07-19 AR ARP050102978A patent/AR053090A1/es not_active Application Discontinuation
- 2005-07-19 MY MYPI20053287A patent/MY139689A/en unknown
- 2005-07-20 CA CA002574594A patent/CA2574594A1/en not_active Abandoned
- 2005-07-20 EP EP05773226A patent/EP1781660A1/en not_active Withdrawn
- 2005-07-20 AU AU2005267120A patent/AU2005267120B2/en not_active Ceased
- 2005-07-20 CN CNA2005800317167A patent/CN101084218A/zh active Pending
- 2005-07-20 AP AP2007003924A patent/AP2007003924A0/xx unknown
- 2005-07-20 EA EA200700220A patent/EA200700220A1/ru unknown
- 2005-07-20 US US11/185,599 patent/US7741324B2/en not_active Expired - Fee Related
- 2005-07-20 WO PCT/US2005/025891 patent/WO2006012422A1/en not_active Ceased
- 2005-07-20 RU RU2007106068/04A patent/RU2007106068A/ru not_active Application Discontinuation
- 2005-07-20 MX MX2007000822A patent/MX2007000822A/es active IP Right Grant
- 2005-07-20 JP JP2007522756A patent/JP4918038B2/ja not_active Expired - Fee Related
- 2005-07-20 BR BRPI0513565-6A patent/BRPI0513565A/pt not_active IP Right Cessation
- 2005-07-20 KR KR1020077003827A patent/KR20070035087A/ko not_active Ceased
2007
- 2007-01-18 IL IL180806A patent/IL180806A0/en unknown
- 2007-02-16 NO NO20070917A patent/NO20070917L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2574594A1 (en)	2006-02-02
IL180806A0 (en)	2007-06-03
EP1781660A1 (en)	2007-05-09
TW200613306A (en)	2006-05-01
AU2005267120A1 (en)	2006-02-02
AR053090A1 (es)	2007-04-25
WO2006012422A1 (en)	2006-02-02
BRPI0513565A (pt)	2008-05-06
EA200700220A1 (ru)	2007-08-31
US7741324B2 (en)	2010-06-22
CN101084218A (zh)	2007-12-05
JP2008507546A (ja)	2008-03-13
AU2005267120B2 (en)	2011-06-02
US20060019957A1 (en)	2006-01-26
MX2007000822A (es)	2007-04-02
RU2007106068A (ru)	2008-08-27
JP4918038B2 (ja)	2012-04-18
KR20070035087A (ko)	2007-03-29
AP2007003924A0 (en)	2007-02-28
MY139689A (en)	2009-10-30

Legal Events

Date	Code	Title	Description
2011-02-28	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20070917L (no)	2007-03-19	Imidazotriaziner som protein-kinaseinhibitorer
NO20062136L (no)	2006-06-26	Imidazopyrazintyrosin-kinaseinhibitorer
NO20065727L (no)	2006-12-12	Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
NO20064895L (no)	2006-12-19	6,6-Bisykliske ring-substituerte heterobisykliske protein-kinase inhibitorer
NO20082508L (no)	2008-07-31	Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20083918L (no)	2008-11-12	Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
NO20073140L (no)	2007-06-20	Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
MY148851A (en)	2013-06-14	Dihydropyridine derivatives as useful as protein kinase inhibitors
NO20084747L (no)	2008-11-25	Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
NO20080675L (no)	2008-03-13	P38-Map kinaseinhibitorer og metoder for deres anvendelse
WO2008094992A3 (en)	2008-12-04	2-aminopyridine derivatives useful as kinase inhibitors
EA200870373A1 (ru)	2009-04-28	Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ
NO20082026L (no)	2008-06-25	Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20064976L (no)	2006-10-31	Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20084418L (no)	2008-12-23	Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
SG170828A1 (en)	2011-05-30	Deazapurines useful as inhibitors of janus kinases
NO20071915L (no)	2007-05-18	Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
NO20072747L (no)	2007-07-31	Fremgangsmate for fremstilling av indazolforbindelser
NO20076659L (no)	2008-03-18	Pyrrolo(2,3-B)pyridinderivater som protein kinase inhibitorer
WO2007087283A3 (en)	2007-09-13	Thiophene-carboxamides useful as inhibitors of protein kinases
NO20062763L (no)	2006-09-11	Pyrrolotriazinforbindelser som kinaseinhibitorer
MX2009009590A (es)	2009-11-10	Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2009004716A (es)	2009-07-17	Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
NO20084435L (no)	2008-11-28	C-MET proteinkinaseinhibitorer
NO20070453L (no)	2007-01-24	Kondenserte heterocykliske kinase inhibitorer